Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
Takeda's Rich Pipeline Optionality Is Worth A 'Buy'
Takeda Pharmaceutical Q4 Earnings Call Highlights
Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
Takeda's immune disease drug meets main goal of mid-to-late stage trial
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
Assetmark Inc. Buys 33,902 Shares of Takeda Pharmaceutical Co. $TAK
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
My Top 4 Pharma Picks Under Rising Geopolitical Risk
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Takeda Pharmaceutical Co. $TAK Shares Acquired by JPMorgan Chase & Co.
Takeda Pharmaceutical Company Limited (TAK) Discusses Zasocitinib Phase III Psoriasis Data and Commercial Strategy Transcript
Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
TrumpRx lists many medicines at prices higher than paid in UK
Takeda Pharmaceutical Company Limited (TAK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
ABC Arbitrage SA Invests $8.37 Million in Takeda Pharmaceutical Co. $TAK
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery
Takeda deepens AI drug discovery push with $1.7 billion Iambic deal
Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules
Takeda Tests New Highs, But Struggles To Find Entyvio Successor
Takeda Pharmaceutical Company Limited (TAK) Q3 2026 Earnings Call Transcript
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
Dynasty Wealth Management LLC Takes Position in Takeda Pharmaceutical Co. $TAK
Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
Takeda Pharmaceutical (NYSE:TAK) vs. Siga Technologies (NASDAQ:SIGA) Head-To-Head Review
Takeda Pharmaceutical Co. $TAK Shares Sold by Arrowstreet Capital Limited Partnership
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
Fisher Asset Management LLC Acquires 46,490 Shares of Takeda Pharmaceutical Co. $TAK
Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
Boston Partners Has $1.64 Million Stock Holdings in Takeda Pharmaceutical Co. $TAK
AlphaCore Capital LLC Takes $192,000 Position in Takeda Pharmaceutical Co. $TAK
US FDA investigates death tied to Takeda's blood disorder drug
Beacon Biosignals Announces Multi-Year Expansion of Strategic Collaboration with Takeda to Advance Narcolepsy Diagnosis and Neurobiomarker Discovery
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
New Phase 3 Data Show Takeda's Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
10,225 Shares in Takeda Pharmaceutical Co. $TAK Purchased by Focus Partners Advisor Solutions LLC
Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript
Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges